Publication

The Life Sciences Tenant Q2 2024

Article

Contacts & Related Research

In the first half of 2024, U.S. life sciences venture capital funding surged by nearly 30% compared to the same period in 2023. If this investment trend continues, it has the potential to stimulate leasing activity and chip away at the oversupply of space.

 

Key Takeaways:

  • Investors are showing increased interest in life sciences companies that have progressed into clinical trials with promising data outcomes.
  • A substantial amount of the life sciences development pipeline is set to be delivered through the end of the year, adding space to a market that is already saturated.
  • Smaller leases have been the primary driver of demand nationwide in the first half of the year, as many occupiers remain cost-conscious.

Download the full report